【摘要】 慢性硬膜下血肿是常见神经外科疾病，可导致头痛、意识障碍、神经功能损伤等症状，严重时可危及患者生命。有症状的慢性硬膜下血肿通常采用钻孔引流术治疗。术后出血和血肿复发仍然是主要的并发症。抗血小板药物在心脑血管疾病的预防和治疗中具有重要的作用，能够有效降低心肌梗死和缺血性脑卒中的发生率。因此，对于长期服用抗血小板药物的慢性硬膜下血肿患者，钻孔引流术后何时重启抗血小板治疗仍存在争议。过早重启抗血小板药物治疗可能增加术后出血和血肿复发的风险，而延迟重启抗血小板药物治疗则可能增加血栓形成的风险，导致血栓栓塞事件。因此，合理评估重启抗血小板治疗的时机对于改善CSDH患者预后至关重要。本文就CSDH钻孔引流术后重启抗血小板治疗的研究进展进行综述。更多还原

【Abstract】 Chronic subdural hematoma(CSDH) is a common neurosurgical disease that can lead to symptoms such as headache, impaired consciousness, and neurological deficits, and may be life-threatening in severe cases. Symptomatic CSDH is typically treated with burr hole drainage. Postoperative hemorrhage and hematoma recurrence remain major complications. Antiplatelet drugs play a crucial role in the prevention and treatment of cardiovascular and cerebrovascular diseases, effectively reducing the incidence of myocardial infarction and ischemic stroke. Therefore, for CSDH patients on long-term antiplatelet medication, the optimal timing for restarting antiplatelet therapy after burr hole drainage remains controversial. Restarting antiplatelet therapy too early may increase the risk of postoperative bleeding and hematoma recurrence, while delaying its restart may elevate the risk of thrombosis, leading to thromboembolic events. Thus, a reasonable assessment of the timing for restarting antiplatelet therapy is crucial for improving the prognosis of CSDH patients. This article reviews the research progress on restarting antiplatelet therapy after burr hole drainage for CSDH.更多还原